Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)
Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –
Alnylam Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Alnylam Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $5.01B, up 56.2% year over year. For fiscal 2025 it was $3.71B, up 65.2% from the year before. Over ten years it grew 43.5% a year on average. The highest annual figure on record is $3.71B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71B | +65.2% |
| FY2024 | Dec 31, 2024 | $2.25B | +23.0% |
| FY2023 | Dec 31, 2023 | $1.83B | +76.2% |
| FY2022 | Dec 31, 2022 | $1.04B | +22.9% |
| FY2021 | Dec 31, 2021 | $844.29M | +71.3% |
| FY2020 | Dec 31, 2020 | $492.85M | +124.3% |
| FY2019 | Dec 31, 2019 | $219.75M | +193.4% |
| FY2018 | Dec 31, 2018 | $74.91M | -16.7% |
| FY2017 | Dec 31, 2017 | $89.91M | +90.7% |
| FY2016 | Dec 31, 2016 | $47.16M | -52.9% |
| FY2010 | Dec 31, 2010 | $100.04M | -0.5% |
| FY2009 | Dec 31, 2009 | $100.53M | +4.5% |
| FY2008 | Dec 31, 2008 | $96.16M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.46B | +16.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.29B | +66.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.17B | +96.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.10B | +84.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.25B | +149.3% |
| Q2 FY2025 | Jun 30, 2025 | $773.69M | +17.3% |
| Q1 FY2025 | Mar 31, 2025 | $594.19M | +20.2% |
| Q4 FY2024 | Dec 31, 2024 | $593.17M | +34.9% |
| Q3 FY2024 | Sep 30, 2024 | $500.92M | -33.3% |
| Q2 FY2024 | Jun 30, 2024 | $659.83M | +107.0% |
| Q1 FY2024 | Mar 31, 2024 | $494.33M | +54.8% |
| Q4 FY2023 | Dec 31, 2023 | $439.72M | +31.2% |
| Q3 FY2023 | Sep 30, 2023 | $750.53M | +184.0% |
| Q2 FY2023 | Jun 30, 2023 | $318.75M | +41.8% |
| Q1 FY2023 | Mar 31, 2023 | $319.29M | +49.7% |
| Q4 FY2022 | Dec 31, 2022 | $335.04M | +29.6% |
| Q3 FY2022 | Sep 30, 2022 | $264.31M | +40.9% |
| Q2 FY2022 | Jun 30, 2022 | $224.82M | +1.9% |
| Q1 FY2022 | Mar 31, 2022 | $213.26M | +20.1% |
| Q4 FY2021 | Dec 31, 2021 | $258.54M | +58.1% |
| Q3 FY2021 | Sep 30, 2021 | $187.63M | +49.1% |
| Q2 FY2021 | Jun 30, 2021 | $220.55M | +112.1% |
| Q1 FY2021 | Mar 31, 2021 | $177.57M | +78.5% |
| Q4 FY2020 | Dec 31, 2020 | $163.56M | +128.2% |
| Q3 FY2020 | Sep 30, 2020 | $125.85M | +79.6% |
| Q2 FY2020 | Jun 30, 2020 | $103.96M | +132.5% |
| Q1 FY2020 | Mar 31, 2020 | $99.48M | +198.8% |
| Q4 FY2019 | Dec 31, 2019 | $71.68M | +240.8% |
| Q3 FY2019 | Sep 30, 2019 | $70.06M | +3286.2% |
| Q2 FY2019 | Jun 30, 2019 | $44.71M | +49.5% |
| Q1 FY2019 | Mar 31, 2019 | $33.29M | +52.0% |
| Q4 FY2018 | Dec 31, 2018 | $21.03M | -44.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.07M | -87.9% |
| Q2 FY2018 | Jun 30, 2018 | $29.91M | +87.7% |
| Q1 FY2018 | Mar 31, 2018 | $21.90M | +15.5% |
| Q4 FY2017 | Dec 31, 2017 | $37.92M | – |
| Q3 FY2017 | Sep 30, 2017 | $17.10M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.93M | – |
| Q1 FY2017 | Mar 31, 2017 | $18.96M | – |
See a number that looks wrong?